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Letters
Increased mtDNA Copy Number Does Not
Protect Against LHON
We read with interest the article by Bianco et al.1 about the
mitochondrial DNA (mtDNA) copy number in 12 patients with
Leber’s hereditary optic neuropathy (LHON) and 18 asymp-
tomatic carriers of the primary LHON mutations m.11778G>A
and m.3460G>A, respectively. The authors interpreted the
increased mtDNA copy number in lymphocytes as a protective
effect in LHON mutation carriers.1 We have the following
comments and concerns.
We do not agree with the conclusion that an increased
mtDNA copy number is protective against clinical manifesta-
tions of a mutation. It is also conceivable that an increased
mtDNA copy number represents a nonspecific or compensa-
tory mechanism that has no preventive effect at all. This
compensatory effect could be weaker in patients as compared
with carriers. Figure 1A nicely shows that the copy number is
independent of the heteroplasmy rate, suggesting that with
increase of the mtDNA copy number, mutated and wild-type
mtDNA proportionally increase. If mitochondria containing
wild-type mtDNA and mitochondria containing mutated
mtDNA proportionally increase in number, why should this
have a protective effect as implicated by the authors? Did the
mtDNA copy number correlate with the disease onset or the
disease severity? Was the mtDNA copy number measured in
different tissues? Possibly, mtDNA copy number is tissue-
specific and variable between different tissues.
We do not agree with the statement that LHON is the most
common of the mitochondrial disorders (MIDs).1 Although
large-scale epidemiological data about the frequency of specific
and nonspecific MIDs are lacking, there are some indications
that nonspecific mitochondrial multiorgan disorder syndromes
with a frequency of 1:400 are the MIDs most frequently
occurring.2
We also do not agree with the notion that mtDNA itself
contributes to the copy number and the heteroplasmy rate. The
heteroplasmy rate is predominantly influenced by the bottle-
neck effect during early oogenesis and probably also during
mitotic segregation of the mutation in postmitotic tissues.
Which is the mechanism by which mtDNA should regulate
mtDNA copy number and heteroplasmy rate?
One of the factors that may convert an asymptomatic
mutation carrier into a clinically manifesting patient is oxidative
stress due to increase in the amount of reactive oxygen species
or reduction of the antioxidative defense.3 Did the authors
measure oxidative stress and was there a correlation between
any of the oxidative stress parameters and the mtDNA copy
number? Another factor could be the haplotype.4 Did all
included patients carry the same haplotype?
Smoking may be a risk factor for the conversion of
asymptomatic mutation carrier into patients manifesting with
LHON. According to Table 1, only one patient was a smoker. Is
it conceivable that this figure is not reliable?
Why did only 2 of the 12 LHON patients receive idebenone?
Idebenone has been shown to be beneficial in a few patients
with LHON, particularly if given shortly after onset of the
clinical manifestations.5 In only one of the two patients who
received idebenone was the copy number determined. The
authors state that the effect of idebenone is mentioned in Table
1; however, we could recognize only the information on who
took idebenone and who did not. Only two patients altogether
were taking idebenone, but its effect was neither mentioned in
the results nor in Table 1.
Overall, this interesting study could be more meaningful if
more patients would have been included, if more patients
would have received idebenone, if the effect of idebenone
would have been reported, and if the mtDNA copy number
would have been assessed in more than one tissue.
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